Provectus Biopharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-5.4M | $-4.7M | $-3.1M | $-3.6M | $-5.5M | $-6.7M | $-6.9M | $-8.2M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $1.9K | $7.2K | $8.9K | $10.9K | $12.9K | $13.7K | $14.1K | $14.1K |
| Amortization | — | — | — | — | — | $228.1K | $671.1K | $671.1K |
| Stock-Based Compensation | $1.2M | $1.3M | $2.9K | $3.0K | $23.7K | $134.8K | $23.0K | $80.0K |
| Net Cash from Operating Activities | $-3.3M | $-3.3M | $-2.6M | $-3.0M | $-1.0M | $-4.1M | $-6.2M | $-5.2M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $3.1M | $2.7M | $2.2M | $1.4M | $4.0M | $3.6M | $6.8M | $5.2M |
| Net Change in Cash | $-238.4K | $-537.1K | $-404.9K | $-1.7M | $3.0M | $-493.5K | $539.7K | $-54.5K |
| Free Cash Flow | — | — | — | — | — | — | — | — |